ASO Author Reflections: Indolent Growth and Small Bowel Neuroendocrine Tumor Management.

Abstract

Surgical treatment is central to management of small bowel neuroendocrine tumors (SBNETs). Current controversies include whether to resect asymptomatic primary tumors in the setting of unresectable metastases, the role of minimally invasive surgery, and how best to incorporate/sequence medical treatments. Low SBNET incidence, long event-times, and variability in disease burden, surgical technique, and institutional treatment preferences remain obstacles to conducting randomized surgical trials for SBNETs. With increasing referral of these patients to high-volume centers, cooperation between experienced SBNET clinicians should allow design of high-quality randomized trials to test new treatments and answer key questions.

• Authors: S K Sherman, C G Tran, J R Howe
• Journal: Annals of surgical oncology (Ann Surg Oncol) Vol. 28 Issue 5 Pg. 2752-2753 (May 2021) ISSN: 1534-4681 [Electronic] United States
• PMID: 33566244 (Publication Type: Journal Article)

Topics

• Humans
• Intestinal Neoplasms (surgery)
• Intestine, Small (surgery)
• Neuroendocrine Tumors (surgery)
• Pancreatic Neoplasms
• Stomach Neoplasms